Microsure, a Dutch medical technology company specialising in surgical robotics, has received CE mark approval for its MUSA-3 system and announced the appointment of Alex Joseph as its new Chief Executive Officer, succeeding Iwan van Vijfeijken.

The CE certification enables the company to begin clinical deployment of the MUSA-3 system across Europe, marking its transition from a product development-focused organisation to a clinical medical device company. The next phase will focus on generating clinical evidence, supporting adoption across healthcare institutions, and expanding collaborations with leading medical centres.

Microsure plans to work closely with European hospitals and clinicians to evaluate how the MUSA-3 system enhances super-microsurgical procedures and contributes to improved surgical precision and outcomes.

Designed to assist surgeons during open super-microsurgical interventions, the MUSA-3 system enables more precise, controlled, and stable hand movements. The platform is intended for procedures involving extremely small anatomical structures such as lymphatic vessels, blood vessels, and nerves. Its applications include free flap reconstruction, lymphatic surgery, and peripheral nerve repair.

The leadership transition reflects the company’s strategic shift towards clinical adoption and commercial expansion. Alex Joseph, who has played a key role in the development of the MUSA-3 platform, brings extensive experience in surgical robotics and regulated medical devices.

Commenting on his appointment, Joseph said, “As I step into the role of CEO, Microsure is entering a new phase. With the CE mark now achieved, our focus is on generating clinical evidence and demonstrating the value of our technology in real-world practice.”

The company also acknowledged the contributions of former CEO Iwan van Vijfeijken, who led Microsure through a crucial phase of technological development and regulatory achievement, culminating in the CE approval of the MUSA-3 system.